A hybrid closed loop (HCL) system — also called automated insulin delivery (AID) or artificial pancreas — combines an insulin pump, a continuous glucose monitor, and a control algorithm that automatically adjusts insulin delivery to keep blood glucose in target range. As of 2026, four systems are FDA approved in the US — Tandem Control-IQ, Medtronic SmartGuard (780G), Omnipod 5 SmartAdjust, and Beta Bionics iLet. They consistently improve Time in Range by 10 to 15 percentage points, reduce hypoglycemia, and modestly lower A1C versus multiple daily injections.
What “Hybrid Closed Loop” Means
- Open loop — user manually determines all insulin doses based on glucose meter readings and carb counts
- Sensor-augmented pump — CGM and pump are connected but user makes all decisions; pump may suspend basal at low glucose
- Hybrid closed loop — algorithm automates basal and corrections; user still bolus for meals
- Full closed loop — algorithm handles everything including meals; still in development
How an HCL System Works
- CGM sensor measures glucose every 5 minutes and sends data wirelessly
- Algorithm (on the pump or controller) compares current glucose and trend to a target (typically 100 to 150 mg/dL)
- If glucose is rising or above target, algorithm increases basal or delivers auto-correction bolus
- If glucose is falling or below target, algorithm decreases or suspends basal
- User manually enters meal carbs (or in iLet, announces meal size) for bolus
- Pump delivers insulin via infusion set or pod
- Process repeats every 5 minutes, 24 hours a day
FDA-Approved HCL Systems in the US (2026)
| System | Pump | CGM | Algorithm | Target Glucose | Auto-Corrections | Age Approved |
|---|---|---|---|---|---|---|
| Tandem Control-IQ | t:slim X2, Mobi | Dexcom G6, G7 | Control-IQ | 112.5 mg/dL fixed | Conservative, up to hourly | 6+ (T1D) |
| Medtronic SmartGuard | MiniMed 780G | Guardian 4 | SmartGuard | 100, 110, or 120 | Aggressive, up to hourly | 7+ (T1D) |
| Omnipod 5 | Pod (tubeless) | Dexcom G6, G7, Libre 2 Plus | SmartAdjust | 110-150 adjustable | Via basal modulation | 2+ (T1D), 18+ (T2D) |
| Beta Bionics iLet | iLet bionic pancreas | Dexcom G6, G7 | Adaptive iLet | Adaptive; user picks “usual,” “more,” “less” for meals | Yes | 6+ (T1D) |
Form Factor and User Experience Comparison
| Feature | Control-IQ (t:slim) | Control-IQ (Mobi) | Medtronic 780G | Omnipod 5 | iLet |
|---|---|---|---|---|---|
| Tubing | Tubed | Tubed (short) | Tubed | Tubeless (pod) | Tubed |
| Reservoir | 300 units | 200 units | 300 units | 200 units | 180 units |
| Site change | 2-3 days | 2-3 days | 2-3 days (up to 7 with Extended Set) | 3 days (whole pod) | 2-3 days |
| Phone bolus | View-only | Full | View-only iOS, full Android | Full | Pump-only |
| Carb counting required | Yes | Yes | Yes | Yes | No — meal announcement only |
| Battery | USB rechargeable | Wireless rechargeable | AA battery | Pod battery | Built-in rechargeable |
Clinical Outcomes — What the Trials Show
| Trial | System Tested | TIR Improvement | A1C Change |
|---|---|---|---|
| DCLP3 (Brown 2019) | Control-IQ t:slim X2 | +11 percent (61% to 71%) | -0.33 percent |
| FLAIR (Bergenstal 2021) | Medtronic AHCL (780G precursor) | +10 percent (57% to 67%) | -0.5 percent |
| CLOUD-101 (Garg 2022) | Omnipod 5 | +9 percent adult; +16 percent pediatric | -0.4 to -0.7 percent |
| iLet pivotal (Russell 2022) | iLet bionic pancreas | +5 to +7 percent | -0.5 percent |
Across all four systems, real-world data confirms similar benefits, especially in users transitioning from MDI to AID. Hypoglycemia is consistently reduced. Overnight glucose control improves the most.
Key Differences in Algorithm Behavior
- Most aggressive auto-correction — Medtronic 780G (up to one full correction per hour)
- Most conservative — Tandem Control-IQ (60 percent of calculated correction, only when glucose projected very high)
- Most adjustable target — Omnipod 5 (5 settings, can vary by time of day)
- Simplest user input — iLet (no carb counting; meal announcement only)
- Sleep and exercise modes — Tandem Control-IQ has dedicated activity profiles
Beta Bionics iLet — The Different One
The iLet bionic pancreas takes a unique approach:
- Users do not count carbs — they tell the iLet “usual” or “more” or “less” meal at meal time
- The algorithm adapts to the user over the first few days from total daily insulin patterns
- Targets glucose adaptively rather than at a fixed setpoint
- Simpler setup with fewer user-adjustable settings
- Best for users who find carb counting burdensome
- Trade-off — less user override capability for unusual situations
Indications and Candidates
- Type 1 diabetes — primary indication for all four systems
- Type 2 diabetes — Omnipod 5 approved in adults; others off-label
- Pediatric — Omnipod 5 from age 2, Tandem Control-IQ and iLet from 6, Medtronic 780G from 7
- Pregnancy — increasing use of Tandem Control-IQ and Omnipod 5 with adjusted targets
- Hypoglycemia unawareness — strong indication for HCL
- High A1C on MDI — strong indication if able to manage device complexity
- Athletes — temporary targets help manage exercise
Benefits Across HCL Systems
- Improved Time in Range by 10 to 15 percent
- Reduced hypoglycemia, especially overnight
- Modest A1C improvement (0.3 to 0.7 percentage points)
- Less mental burden — system handles many adjustments automatically
- Better sleep quality — overnight glucose more stable
- Improved quality of life scores in trials
- Easier diabetes management for caregivers of children
Limitations and Drawbacks
- Still requires meal bolusing — except iLet meal announcement
- Site or pod changes every 2 to 3 days — physical wear and skin trauma
- CGM warmup periods — 1 to 2 hours during sensor changes when system runs in manual mode
- Alarm fatigue — frequent CGM and pump alerts can be disruptive
- Hardware reliability — pump or CGM failures require manual backup
- Algorithm exits — under certain conditions (low or high glucose, CGM signal loss) system reverts to manual mode
- Learning curve — typically 1 to 3 months to optimize settings
- Cost — pumps and CGMs add $5,000 to $10,000 per year retail
Cost Overview
| Item | Typical Annual Cost |
|---|---|
| Pump device (amortized over 4-year warranty) | $1,000 to $2,000 |
| Infusion sets or pods | $3,000 to $6,000 |
| CGM (Dexcom G7, Guardian 4, Libre 2 Plus) | $3,000 to $6,000 |
| Insulin (rapid-acting only) | $1,000 to $3,000 |
| Annual retail subtotal | $8,000 to $17,000 |
| Typical out-of-pocket with insurance | $1,500 to $5,000 |
Medicare Part B covers pumps as DME for type 1 diabetes. Commercial insurance generally covers HCL systems for type 1 with prior authorization. Omnipod 5 is often available through pharmacy benefit, which can ease access.
Side Effects and Risks
- Diabetic ketoacidosis — risk from infusion interruption; pumps deliver only rapid-acting insulin so any gap rapidly leads to ketones
- Hypoglycemia — reduced vs MDI but still possible; algorithm settings tuning helps
- Infusion site infection — rare; redness, warmth, pus need same-day care
- Skin reactions to adhesive — both pump tape and CGM
- Lipohypertrophy — minimized by rotation
- Sensor errors — incorrect glucose readings can drive algorithm errors
- Algorithm exits — manual mode requires user vigilance
- Hardware failure — pump or CGM; backup MDI plan essential
What to Discuss with Your Clinician
- Your typical insulin dose (some systems have minimum or maximum daily insulin)
- CGM preference (Dexcom vs Guardian vs Libre)
- Tubed vs tubeless preference
- Phone control importance
- Carb-counting comfort (iLet bypass)
- Activity level and exercise needs
- Skin sensitivity and adhesive history
- Insurance coverage and out-of-pocket cost
- Local diabetes educator and clinician familiarity with each system
Related Reading
For pump fundamentals see how does an insulin pump work. For specific systems see our Omnipod 5, Medtronic 780G, and Tandem Mobi articles. For broader context see insulin therapy, basal-bolus regimens, and all treatment options.
External Resources
The American Diabetes Association Standards of Care 2024 contains AID and HCL system recommendations, and the original FDA medical device database hosts approval documentation for all four systems.
The Bottom Line
Hybrid closed loop systems combine an insulin pump, a continuous glucose monitor, and a control algorithm to automatically adjust insulin delivery — improving Time in Range by 10 to 15 percentage points and reducing hypoglycemia compared with multiple daily injections. Four systems are FDA approved in the US as of 2026 — Tandem Control-IQ (t:slim X2 or Mobi), Medtronic SmartGuard (780G), Omnipod 5 SmartAdjust, and Beta Bionics iLet. They differ in form factor (tubed vs tubeless), reservoir size, target glucose, auto-correction aggressiveness, CGM compatibility, and pediatric age cutoffs. The Medtronic 780G has the most aggressive auto-corrections; Omnipod 5 has the most adjustable target and is tubeless; Tandem Mobi has the smallest form factor and best phone control; iLet eliminates carb counting. All require some user input (meal bolusing or announcements) — fully closed loop systems remain in development. Talk to your endocrinologist and diabetes educator about which HCL system best fits your diabetes type, age, lifestyle, insurance coverage, and willingness to manage device complexity. The right HCL system can be life-changing; the wrong choice can add complexity without benefit.
